Injectable Drug Delivery Technology Market Synopsis

Global Injectable Drug Delivery Technology Market Size Was Valued at USD 709.99 Billion in 2023 and is Projected to Reach USD 2016.83 Billion by 2032, Growing at a CAGR of 12.3 % From 2024-2032.

Injectable drug delivery technology uses needles, syringes, or specialized devices to administer medication directly into the body, bypassing the digestive system. This technology is crucial for treating autoimmune diseases, diabetes, and cancer. Advancements in injectable drug delivery systems have led to innovations like needle-free injectors, auto-injectors, and wearable devices.

• The advantages, demand, and growth of injectable drug delivery technology are significant factors in its increasing popularity and market expansion. Its benefits include precise dosing, rapid action, and improved drug effectiveness, making it a preferred method for medication administration. By delivering drugs directly into the bloodstream, it bypasses the gastrointestinal system, ensuring drug stability and efficacy. This technology also enhances patient adherence, especially with the introduction of user-friendly devices like auto-injectors and wearable injectors.
• Increasing demand for injectable drug delivery technology stems from the rising incidence of chronic conditions such as diabetes, cancer, and autoimmune diseases, where precise dosing and immediate drug effects are crucial. Additionally, advancements in biologics and targeted therapies drive market growth by requiring specialized delivery systems.
• Market expansion is propelled by ongoing research and development efforts focused on improving drug delivery devices, enhancing patient convenience, and addressing emerging therapeutic needs. Moreover, factors such as rising healthcare spending, improved access to advanced medical treatments, and a growing elderly population contribute to the sustained growth of the injectable drug delivery technology market.

Injectable Drug Delivery Technology Market Trend Analysis:

Advancements in Biologics and Targeted Therapies

• Advancements in biologics and targeted therapies serve as key drivers behind the progression of injectable drug delivery technology. Biologics, originating from living organisms, offer highly specialized treatment for various diseases like cancer, autoimmune disorders, and inflammatory ailments. These intricate molecules necessitate tailored delivery systems to ensure precise dosing and efficient delivery to the intended site.
• Targeted therapies, crafted to disrupt specific molecules involved in disease progression, further underline the necessity for advanced drug delivery methods. Injectable delivery systems enable the direct administration of these therapies to affected tissues or cells, maximizing therapeutic effectiveness while minimizing unintended effects.
• Furthermore, the emergence of new biologic drugs and biosimilars demands innovative injectable delivery technologies to enhance patient convenience, compliance, and treatment outcomes. This symbiotic relationship between biologics, targeted therapies, and injectable drug delivery technology propels ongoing innovation in the field, fostering the development of sophisticated delivery systems such as auto-injectors, wearable devices, and microneedle patches. Ultimately, these advancements contribute to elevated patient care and the broadening of treatment options across a diverse spectrum of medical conditions.

Integration of digital health technologies

• The incorporation of digital health technologies presents notable opportunities within the domain of injectable drug delivery technology. By amalgamating conventional drug delivery methods with digital advancements like connected devices, smartphone apps, and remote monitoring capabilities, numerous advantages emerge. This integration enhances patient engagement and adherence through features such as medication reminders, dosage tracking, and instant feedback, empowering patients to take a more proactive role in managing their health and resulting in better treatment outcomes.
• Furthermore, digital technologies allow healthcare providers to remotely monitor patient progress, receive real-time data on medication adherence and effectiveness, and intervene promptly as needed, enabling personalized treatment adjustments and interventions to enhance overall patient care.
• Moreover, the collection and analysis of data generated by digital health technologies provide valuable insights into patient behavior, treatment patterns, and therapeutic efficacy, informing future product development, optimizing treatment protocols, and driving ongoing improvement in injectable drug delivery technology.

Injectable Drug Delivery Technology Market Segment Analysis:

Injectable Drug Delivery Technology Market Segmented on the basis of type, application, and end-users.

By Administration, Subcutaneous segment is expected to dominate the market during the forecast period

• Subcutaneous administration entails delivering medication into the layer of tissue located beneath the skin, offering numerous advantages. Firstly, subcutaneous injections are relatively straightforward to administer, making them conducive to patient self-administration outside clinical settings. This ease of use enhances patient convenience and adherence to prescribed treatments.
• Moreover, subcutaneous injections typically result in a slower and sustained absorption of drugs compared to intravenous injections, ensuring more consistent drug levels over time. This pharmacokinetic profile is advantageous for medications requiring continuous or prolonged therapeutic effects.
• Subcutaneous route provides a larger surface area for drug absorption compared to intramuscular injections, enabling the administration of larger medication volumes if necessary. This adaptability renders subcutaneous delivery suitable for a wide array of therapeutic agents, including biologics, hormones, and vaccines.
• In essence, the prominence of the subcutaneous segment underscores its widespread acceptance due to its convenience, reliable drug delivery, and applicability to various medications, driving its market dominance during the forecasted period.

By Technology, Conventional syringes segment held the largest share of 50 % in 2022

• largest market share in the Injectable Drug Delivery Technology Market by technology was held by the conventional syringes segment, accounting for 50%. Conventional syringes, known for their simplicity and adaptability, have long been a primary method of drug delivery. Their prevalence can be attributed to several factors.
• Conventional syringes offer a straightforward and cost-effective means of administering medications in various healthcare settings. Their ease of use makes them suitable for both healthcare professionals and patients, leading to widespread acceptance. Conventional syringes ensure precise dosage delivery, facilitating accurate medication administration, especially for drugs with specific dosing requirements.
• Additionally, the familiarity and established infrastructure associated with conventional syringes contribute to their market dominance. Healthcare professionals are proficient in their use, and healthcare facilities typically have the necessary equipment readily available, further driving their widespread adoption.

Injectable Drug Delivery Technology Market Regional Insights:

Asia Pacific is Expected to Dominate the Market Over the Forecast period

• The growth of the Injectable Drug Delivery Technology Market is fueled by various factors. Advancements in biologics and targeted therapies are expanding the range of injectable drug delivery systems. These sophisticated medications require precise administration methods for optimal effectiveness. Additionally, the increasing prevalence of chronic diseases like diabetes, cancer, and autoimmune disorders drives the demand for injectable drug delivery technology. These conditions often require regular and accurate dosing for effective management. Moreover, the introduction of innovative delivery devices such as auto-injectors and wearable injectors is enhancing patient convenience and adherence, further boosting market growth.
• The demand for injectable drug delivery technology is also supported by the global increase in healthcare expenditure. Governments and healthcare organizations worldwide are investing in advanced medical technologies, including injectable drug delivery systems, to enhance patient care and treatment outcomes. Furthermore, streamlined regulatory pathways for drug-device combination products encourage innovation and market entry, facilitating the growth of the Injectable Drug Delivery Technology Market.
• Factors such as advancements in medicine, the rise of chronic diseases, and the development of user-friendly injection devices are driving the growth of the Injectable Drug Delivery Technology Market. Governments and healthcare providers are investing in better treatments, and regulations are making it easier for new products to come to market. This steady growth means more options for patients and better chances of successful treatment for various medical conditions.

Injectable Drug Delivery Technology Market Top Key Players:

• Pfizer Inc. (US)
• Merck & Co., Inc. (US)
• Zogenix Inc. (US)
• Liquidia Technologies Inc. (US)
• Akili Interactive Labs, Inc. (US)
• MicroCHIPS (US)
• Microchips Biotech Limited (US)
• Becton, Dickinson and Company (US)
• Baxter International Inc. (US)
• AstraZeneca (UK)
• Sanofi (France)
• Nemera (France)
• Boehringer Ingelheim (Germany)
• B. Braun Melsungen AG (Germany)
• Schott AG (Germany)
• Ypsomed AG (Switzerland)
• Alkermes plc (Ireland)
• Terumo Corporation (Japan)
• Teva Pharmaceuticals Industries Ltd. (Israel), and Other Major Players.

Key Industry Developments in the Injectable Drug Delivery Technology Market:

• In May 2024, DelSiTech Ltd, a clinical-stage drug delivery and development company, announced that it had entered into a Licensing Agreement with an undisclosed global pharmaceutical company. According to the agreement, DelSiTech granted an exclusive global license to its Silica Matrix-based, controlled-release technology for the development and commercialization of an undisclosed long-acting injectable drug product.
• In January 2024, Kindeva Drug Delivery acquired Summit Biosciences Inc., an intranasal drug-delivery CDMO, thereby adding a new drug-delivery platform and expanding Kindeva’s capabilities across a broader range of complex drug-device combination products, including pulmonary, injectable, transdermal, and nasal. Summit’s 55,000-sq.-ft. cGMP facility in Lexington, KY, augmented Kindeva’s global manufacturing footprint, which now includes nine development and manufacturing facilities across the U.S. and U.K.

1. INTRODUCTION
   1. RESEARCH OBJECTIVES
   2. RESEARCH METHODOLOGY
   3. RESEARCH PROCESS
   4. SCOPE AND COVERAGE
      1. Market Definition
      2. Key Questions Answered
   5. MARKET SEGMENTATION
2. EXECUTIVE SUMMARY
3. MARKET OVERVIEW
4. GROWTH OPPORTUNITIES BY SEGMENT
5. MARKET LANDSCAPE
   1. PORTER’S FIVE FORCES ANALYSIS
      1. Bargaining Power Of Supplier
      2. Threat Of New Entrants
      3. Threat Of Substitutes
      4. Competitive Rivalry
      5. Bargaining Power Among Buyers
   2. INDUSTRY VALUE CHAIN ANALYSIS
   3. MARKET DYNAMICS
      1. Drivers
      2. Restraints
      3. Opportunities
      4. Challenges
   4. MARKET TREND ANALYSIS
   5. REGULATORY LANDSCAPE
   6. PESTLE ANALYSIS
   7. PRICE TREND ANALYSIS
   8. PATENT ANALYSIS
   9. TECHNOLOGY EVALUATION
   10. MARKET IMPACT OF THE RUSSIA-UKRAINE WAR
       1. Geopolitical Market Disruptions
       2. Supply Chain Disruptions
       3. Instability in Emerging Markets
   11. ECOSYSTEM
6. INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET BY ADMINISTRATION (2017-2032)
   1. INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET SNAPSHOT AND GROWTH ENGINE
   2. MARKET OVERVIEW
   3. SUBCUTANEOUS
      1. Introduction And Market Overview
      2. Historic And Forecasted Market Size in Value (2017 – 2032F)
      3. Historic And Forecasted Market Size in Volume (2017 – 2032F)
      4. Key Market Trends, Growth Factors And Opportunities
      5. Geographic Segmentation Analysis
   4. INTRAMUSCULAR
   5. INTRAVENOUS
   6. INTRANASAL

6. 1. 1. INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET BY TECHNOLOGY (2017-2032)

      2. 7. INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET SNAPSHOT AND GROWTH ENGINE
         8. MARKET OVERVIEW
         9. CONVENTIONAL SYRINGES
            1. Introduction And Market Overview
            2. Historic And Forecasted Market Size in Value (2017 – 2032F)
            3. Historic And Forecasted Market Size in Volume (2017 – 2032F)
            4. Key Market Trends, Growth Factors And Opportunities
            5. Geographic Segmentation Analysis
         10. NEEDLE-FREE INJECTORS
         11. PRE-FILLED SYRINGES
         12. IMPLANTABLE DRUG DELIVERY SYSTEMS
         13. MICRONEEDLE PATCHES
      3. INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET BY APPLICATION (2017-2032)
         7. INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET SNAPSHOT AND GROWTH ENGINE
         8. MARKET OVERVIEW
         9. DIABETES
            1. Introduction And Market Overview
            2. Historic And Forecasted Market Size in Value (2017 – 2032F)
            3. Historic And Forecasted Market Size in Volume (2017 – 2032F)
            4. Key Market Trends, Growth Factors And Opportunities
            5. Geographic Segmentation Analysis
         10. PAIN MANAGEMENT
         11. ONCOLOGY
         12. AUTOIMMUNE DISEASES
         13. INFECTIOUS DISEASES
      4. INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET BY END-USER (2017-2032)
         0. INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET SNAPSHOT AND GROWTH ENGINE
         1. MARKET OVERVIEW
         2. HOSPITALS
            1. Introduction And Market Overview
            2. Historic And Forecasted Market Size in Value (2017 – 2032F)
            3. Historic And Forecasted Market Size in Volume (2017 – 2032F)
            4. Key Market Trends, Growth Factors And Opportunities
            5. Geographic Segmentation Analysis
         3. CLINICS
         4. HOMECARE SETTINGS
         5. AMBULATORY SURGICAL CENTRES
      5. COMPANY PROFILES AND COMPETITIVE ANALYSIS
         0. COMPETITIVE LANDSCAPE
            1. Competitive Positioning
            2. Injectable Drug Delivery Technology Market Share By Manufacturer (2022)
            3. Industry BCG Matrix
            4. Heat Map Analysis
            5. Mergers & Acquisitions
         1. PFIZER INC. (US)
            1. Company Overview
            2. Key Executives
            3. Company Snapshot
            4. Role of the Company in the Market
            5. Sustainability and Social Responsibility
            6. Operating Business Segments
            7. Product Portfolio
            8. Business Performance (Production Volume, Sales Volume, Sales Margin, Production Capacity, Capacity Utilization Rate)
            9. Key Strategic Moves And Recent Developments
            10. SWOT Analysis
         2. MERCK & CO., INC. (US)
         3. ZOGENIX INC. (US)
         4. LIQUIDIA TECHNOLOGIES INC. (US)
         5. AKILI INTERACTIVE LABS, INC. (US)
         6. MICROCHIPS (US)
         7. MICROCHIPS BIOTECH LIMITED (US)
         8. BECTON, DICKINSON AND COMPANY (US)
         9. BAXTER INTERNATIONAL INC. (US)
         10. ASTRAZENECA (UK)
         11. SANOFI (FRANCE)
         12. NEMERA (FRANCE)
         13. BOEHRINGER INGELHEIM (GERMANY)
         14. B. BRAUN MELSUNGEN AG (GERMANY)
         15. SCHOTT AG (GERMANY)
         16. YPSOMED AG (SWITZERLAND)
         17. ALKERMES PLC (IRELAND)
         18. TERUMO CORPORATION (JAPAN)
         19. TEVA PHARMACEUTICALS INDUSTRIES LTD. (ISRAEL)
      6. GLOBAL INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET BY REGION
         0. OVERVIEW
         1. NORTH AMERICA
            1. Key Market Trends, Growth Factors And Opportunities
            2. Key Manufacturers
            3. Historic And Forecasted Market Size By Administration
            4. Historic And Forecasted Market Size By Technology
            5. Historic And Forecasted Market Size By Application
            6. Historic And Forecasted Market Size By End-User
            7. Historic And Forecasted Market Size By Country
               1. USA
               2. Canada
               3. Mexico
         2. EASTERN EUROPE
            1. Key Market Trends, Growth Factors And Opportunities
            2. Key Manufacturers
            3. Historic And Forecasted Market Size By Segments
            4. Historic And Forecasted Market Size By Country
               1. Russia
               2. Bulgaria
               3. The Czech Republic
               4. Hungary
               5. Poland
               6. Romania
               7. Rest Of Eastern Europe
         3. WESTERN EUROPE
            1. Key Market Trends, Growth Factors And Opportunities
            2. Key Manufacturers
            3. Historic And Forecasted Market Size By Segments
            4. Historic And Forecasted Market Size By Country
               1. Germany
               2. United Kingdom
               3. France
               4. The Netherlands
               5. Italy
               6. Spain
               7. Rest Of Western Europe
         4. ASIA PACIFIC
            1. Key Market Trends, Growth Factors And Opportunities
            2. Key Manufacturers
            3. Historic And Forecasted Market Size By Segments
            4. Historic And Forecasted Market Size By Country
               1. China
               2. India
               3. Japan
               4. South Korea
               5. Malaysia
               6. Thailand
               7. Vietnam
               8. The Philippines
               9. Australia
               10. New-Zealand
               11. Rest Of APAC
         5. MIDDLE EAST & AFRICA
            1. Key Market Trends, Growth Factors And Opportunities
            2. Key Manufacturers
            3. Historic And Forecasted Market Size By Segments
            4. Historic And Forecasted Market Size By Country
               1. Turkey
               2. Bahrain
               3. Kuwait
               4. Saudi Arabia
               5. Qatar
               6. UAE
               7. Israel
               8. South Africa
         6. SOUTH AMERICA
            1. Key Market Trends, Growth Factors And Opportunities
            2. Key Manufacturers
            3. Historic And Forecasted Market Size By Segments
            4. Historic And Forecasted Market Size By Country
               1. Brazil
               2. Argentina
               3. Rest of South America
      7. INVESTMENT ANALYSIS
      8. ANALYST VIEWPOINT AND CONCLUSION
         0. Recommendations and Concluding Analysis
         1. Potential Market Strategies

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET COMPETITIVE RIVALRY
TABLE 005. INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET THREAT OF NEW ENTRANTS
TABLE 006. INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET THREAT OF SUBSTITUTES
TABLE 007. INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET BY TYPE
TABLE 008. CONVENTIONAL DRUG DELIVERY MARKET OVERVIEW (2016-2028)
TABLE 009. NOVEL DRUG DELIVERY MARKET OVERVIEW (2016-2028)
TABLE 010. INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET BY APPLICATION
TABLE 011. APPLICATION A MARKET OVERVIEW (2016-2028)
TABLE 012. APPLICATION B MARKET OVERVIEW (2016-2028)
TABLE 013. APPLICATION C MARKET OVERVIEW (2016-2028)
TABLE 014. NORTH AMERICA INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE (2016-2028)
TABLE 015. NORTH AMERICA INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY APPLICATION (2016-2028)
TABLE 016. N INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY (2016-2028)
TABLE 017. EUROPE INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE (2016-2028)
TABLE 018. EUROPE INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY APPLICATION (2016-2028)
TABLE 019. INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY (2016-2028)
TABLE 020. ASIA PACIFIC INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE (2016-2028)
TABLE 021. ASIA PACIFIC INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY APPLICATION (2016-2028)
TABLE 022. INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY (2016-2028)
TABLE 023. MIDDLE EAST & AFRICA INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE (2016-2028)
TABLE 024. MIDDLE EAST & AFRICA INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY APPLICATION (2016-2028)
TABLE 025. INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY (2016-2028)
TABLE 026. SOUTH AMERICA INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE (2016-2028)
TABLE 027. SOUTH AMERICA INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY APPLICATION (2016-2028)
TABLE 028. INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY COUNTRY (2016-2028)
TABLE 029. ALKERMES: SNAPSHOT
TABLE 030. ALKERMES: BUSINESS PERFORMANCE
TABLE 031. ALKERMES: PRODUCT PORTFOLIO
TABLE 032. ALKERMES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 032. GENENTECH: SNAPSHOT
TABLE 033. GENENTECH: BUSINESS PERFORMANCE
TABLE 034. GENENTECH: PRODUCT PORTFOLIO
TABLE 035. GENENTECH: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 035. BEND RESEARCH: SNAPSHOT
TABLE 036. BEND RESEARCH: BUSINESS PERFORMANCE
TABLE 037. BEND RESEARCH: PRODUCT PORTFOLIO
TABLE 038. BEND RESEARCH: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 038. QLT: SNAPSHOT
TABLE 039. QLT: BUSINESS PERFORMANCE
TABLE 040. QLT: PRODUCT PORTFOLIO
TABLE 041. QLT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 041. ENDOCYTE: SNAPSHOT
TABLE 042. ENDOCYTE: BUSINESS PERFORMANCE
TABLE 043. ENDOCYTE: PRODUCT PORTFOLIO
TABLE 044. ENDOCYTE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 044. BIND BIOSCIENCES: SNAPSHOT
TABLE 045. BIND BIOSCIENCES: BUSINESS PERFORMANCE
TABLE 046. BIND BIOSCIENCES: PRODUCT PORTFOLIO
TABLE 047. BIND BIOSCIENCES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 047. UCB GROUP (UCB): SNAPSHOT
TABLE 048. UCB GROUP (UCB): BUSINESS PERFORMANCE
TABLE 049. UCB GROUP (UCB): PRODUCT PORTFOLIO
TABLE 050. UCB GROUP (UCB): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 050. PRESAGE BIOSCIENCE: SNAPSHOT
TABLE 051. PRESAGE BIOSCIENCE: BUSINESS PERFORMANCE
TABLE 052. PRESAGE BIOSCIENCE: PRODUCT PORTFOLIO
TABLE 053. PRESAGE BIOSCIENCE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 053. POLYMER FACTORY: SNAPSHOT
TABLE 054. POLYMER FACTORY: BUSINESS PERFORMANCE
TABLE 055. POLYMER FACTORY: PRODUCT PORTFOLIO
TABLE 056. POLYMER FACTORY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 056. MICROCHIPS: SNAPSHOT
TABLE 057. MICROCHIPS: BUSINESS PERFORMANCE
TABLE 058. MICROCHIPS: PRODUCT PORTFOLIO
TABLE 059. MICROCHIPS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 059. PEARL THERAPEUTICS: SNAPSHOT
TABLE 060. PEARL THERAPEUTICS: BUSINESS PERFORMANCE
TABLE 061. PEARL THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 062. PEARL THERAPEUTICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 062. PIEDMONT PHARMACEUTICALS: SNAPSHOT
TABLE 063. PIEDMONT PHARMACEUTICALS: BUSINESS PERFORMANCE
TABLE 064. PIEDMONT PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 065. PIEDMONT PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 065. ZOGENIX: SNAPSHOT
TABLE 066. ZOGENIX: BUSINESS PERFORMANCE
TABLE 067. ZOGENIX: PRODUCT PORTFOLIO
TABLE 068. ZOGENIX: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 068. LIQUIDIA TECHNOLOGIES: SNAPSHOT
TABLE 069. LIQUIDIA TECHNOLOGIES: BUSINESS PERFORMANCE
TABLE 070. LIQUIDIA TECHNOLOGIES: PRODUCT PORTFOLIO
TABLE 071. LIQUIDIA TECHNOLOGIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 071. IMPAX LABORATORIES: SNAPSHOT
TABLE 072. IMPAX LABORATORIES: BUSINESS PERFORMANCE
TABLE 073. IMPAX LABORATORIES: PRODUCT PORTFOLIO
TABLE 074. IMPAX LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 074. BOEHRINGER INGELHEIM: SNAPSHOT
TABLE 075. BOEHRINGER INGELHEIM: BUSINESS PERFORMANCE
TABLE 076. BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO
TABLE 077. BOEHRINGER INGELHEIM: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 077. CROSSJECT MEDICAL TECHNOLOGY: SNAPSHOT
TABLE 078. CROSSJECT MEDICAL TECHNOLOGY: BUSINESS PERFORMANCE
TABLE 079. CROSSJECT MEDICAL TECHNOLOGY: PRODUCT PORTFOLIO
TABLE 080. CROSSJECT MEDICAL TECHNOLOGY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 080. APOGEE TECHNOLOGY: SNAPSHOT
TABLE 081. APOGEE TECHNOLOGY: BUSINESS PERFORMANCE
TABLE 082. APOGEE TECHNOLOGY: PRODUCT PORTFOLIO
TABLE 083. APOGEE TECHNOLOGY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 083. PULMATRIX: SNAPSHOT
TABLE 084. PULMATRIX: BUSINESS PERFORMANCE
TABLE 085. PULMATRIX: PRODUCT PORTFOLIO
TABLE 086. PULMATRIX: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 086. MEDICAGO: SNAPSHOT
TABLE 087. MEDICAGO: BUSINESS PERFORMANCE
TABLE 088. MEDICAGO: PRODUCT PORTFOLIO
TABLE 089. MEDICAGO: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET OVERVIEW BY TYPE
FIGURE 012. CONVENTIONAL DRUG DELIVERY MARKET OVERVIEW (2016-2028)
FIGURE 013. NOVEL DRUG DELIVERY MARKET OVERVIEW (2016-2028)
FIGURE 014. INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET OVERVIEW BY APPLICATION
FIGURE 015. APPLICATION A MARKET OVERVIEW (2016-2028)
FIGURE 016. APPLICATION B MARKET OVERVIEW (2016-2028)
FIGURE 017. APPLICATION C MARKET OVERVIEW (2016-2028)
FIGURE 018. NORTH AMERICA INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 019. EUROPE INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 020. ASIA PACIFIC INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 021. MIDDLE EAST & AFRICA INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 022. SOUTH AMERICA INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET OVERVIEW BY COUNTRY (2016-2028)